SEC Form 4 · accession 0001209191-15-030049
ChemoCentryx, Inc. · CCXI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J. Schall
Officer — President and CEO · Director
Period of report
Mar 25, 2015
Accepted (ET)
Mar 27, 2015 · 8:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001340652
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 25, 2015 | M | 900 | $0.60 | A | 2,149,567 | D | |
| Common StockF2,F3 | Mar 25, 2015 | S | 900 | $7.5689 | D | 2,148,667 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $0.60 | Mar 25, 2015 | M | 900 | D | May 5, 2005 | May 5, 2015 | Common Stock | 900 | 24,267 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Shares sold are associated with stock options which will expire in May 2015.
- F3Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.51 to $7.67 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- F4As of March 25, 2015 and prior to this transaction, the option fully vested.